Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Katsuhiko Nagase

Phase I Study of Vorinostat With Gefitinib in BIM Deletion Polymorphism/Egfr Mutation Double‐positive Lung Cancer

Cancer Science

English

Related publications

Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC With EGFR Mutation

Cancer Genomics and Proteomics

English

Effects of Antacids on Clinical Efficacy of Gefitinib in Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)

2017

English

Phase I/Ii Study of Gefitinib (Iressa®) and Vorinostat (IVORI) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology

English

Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib

English

Vorinostat Enhances Gefitinib‑induced Cell Death Through Reactive Oxygen Species‑dependent Cleavage of HSP90 and Its Clients in Non‑small Cell Lung Cancer With the EGFR Mutation

English

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

Gefitinib Induces Premature Senescence in Non-Small Cell Lung Cancer Cells With or Without EGFR Gene Mutation

English

P3.01-75 RELAY+, an Exploratory Study of Gefitinib With Ramucirumab in Untreated Patients With EGFR Mutation-Positive Metastatic NSCLC

Journal of Thoracic Oncology

English

The Profile of Lung Adenocarcinoma Patients With Positive EGFR Mutation

Green Medical Journal

2020

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Katsuhiko Nagase

Phase I Study of Vorinostat With Gefitinib in BIM Deletion Polymorphism/Egfr Mutation Double‐positive Lung Cancer

Related publications

Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC With EGFR Mutation

Effects of Antacids on Clinical Efficacy of Gefitinib in Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Phase I/Ii Study of Gefitinib (Iressa®) and Vorinostat (IVORI) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib

Vorinostat Enhances Gefitinib‑induced Cell Death Through Reactive Oxygen Species‑dependent Cleavage of HSP90 and Its Clients in Non‑small Cell Lung Cancer With the EGFR Mutation

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Gefitinib Induces Premature Senescence in Non-Small Cell Lung Cancer Cells With or Without EGFR Gene Mutation

P3.01-75 RELAY+, an Exploratory Study of Gefitinib With Ramucirumab in Untreated Patients With EGFR Mutation-Positive Metastatic NSCLC

The Profile of Lung Adenocarcinoma Patients With Positive EGFR Mutation